Cargando…

Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiao, Ying Ann, Zhang, Huiliang, Sweetwyne, Mariya, Whitson, Jeremy, Ting, Ying Sonia, Basisty, Nathan, Pino, Lindsay K, Quarles, Ellen, Nguyen, Ngoc-Han, Campbell, Matthew D, Zhang, Tong, Gaffrey, Matthew J, Merrihew, Gennifer, Wang, Lu, Yue, Yongping, Duan, Dongsheng, Granzier, Henk L, Szeto, Hazel H, Qian, Wei-Jun, Marcinek, David, MacCoss, Michael J, Rabinovitch, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377906/
https://www.ncbi.nlm.nih.gov/pubmed/32648542
http://dx.doi.org/10.7554/eLife.55513
Descripción
Sumario:Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.